The minor spliceosome offers a therapeutically viable target for the treatment of a broad spectrum of cancers
K. Doggett, K. J. Morgan, S. Mieruszynski, B. B. Williams, A. M. Olthof, A. L. Garnham, M. J. G. Milevskiy, L. Whitehead, J. Coates, M. Buchert, R. J. O'Donoghue, T. E. Hall, Z. Gong, T. L. Putoczki, M. Ernst, , J. K. Heath
This study shows that targeting the minor spliceosome, specifically Rnpc3, reduces tumor burden in multiple cancer models and is associated with poor patient survival in cancer transcriptomes.
bioRxiv · Dec 9, 2021Cancer Biology